Cargando…
Chemotherapy-induced peripheral neuropathy. Part II. Prevention
The incidence of chemotherapy-induced peripheral neuropathy (CIPN) in the population of cancer patients is estimated at 3–7% in cytostatic monotherapy and as high as 38% in the case of polytherapy. While testing drugs that may reduce the damage to the peripheral nervous system, particular attention...
Autor principal: | Brzeziński, Krzysztof |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687410/ https://www.ncbi.nlm.nih.gov/pubmed/23788891 http://dx.doi.org/10.5114/wo.2012.29296 |
Ejemplares similares
-
Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity
por: Sałat, Kinga
Publicado: (2020) -
Chemotherapy-induced polyneuropathy. Part I. Pathophysiology
por: Brzeziński, Krzysztof
Publicado: (2012) -
Chemotherapy-induced peripheral neuropathy
por: Zhang, Xia, et al.
Publicado: (2017) -
Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy
por: Sałat, Kinga
Publicado: (2020) -
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
por: Zajączkowska, Renata, et al.
Publicado: (2019)